Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharm Pract ; 36(5): 1108-1112, 2023 Oct.
Article in English | MEDLINE | ID: mdl-35414327

ABSTRACT

Background: In April 2020, pharmacists were added as medical providers under Idaho Medicaid in response to recent scope expansion for pharmacists and to increase beneficiaries' access to coronavirus disease 2019 (COVID-19) testing and services. The COVID-19 pandemic prompted expedited Medicaid enrollment for pharmacists but did not address coverage of medical services provided to privately insured individuals for pharmacy-based testing services. Objective: This study aimed to describe processes used by independently owned, community-based pharmacies in Idaho to credential with private insurers and report outcomes. Methods: Relevant information and forms required to credential with the four major payers in the state of Idaho were collected. Packets were obtained via medical insurers' websites and by direct contact. Questions that arose from community pharmacists during the submission process were collected and answered on a shared spreadsheet, and insurance representatives were contacted directly to resolve questions. Results: Eight out of 13 participating pharmacies submitted an average of three credentialing packets for their facilities. Thirty-five pharmacists also submitted an average of four credentialing packets for themselves. As of mid-May 2021, nearly 20 weeks after submission, only 67 out of 129 pharmacists had received word regarding the status of their applications. Less than half of all pharmacist applications were approved (after their first attempt). Conclusion: Efforts to support the education of both pharmacists and medical insurers may streamline the credentialing processes in the future.


Subject(s)
COVID-19 , Community Pharmacy Services , Pharmacies , Humans , Pandemics , COVID-19 Testing , Credentialing , Pharmacists
2.
J Am Pharm Assoc (2003) ; 62(1): 253-259, 2022.
Article in English | MEDLINE | ID: mdl-34535408

ABSTRACT

BACKGROUND: The coronavirus disease Rapid Antigen Testing Expansion Program (Program) employed a drive-thru model to maximize pharmacy staff and the public's safety. OBJECTIVES: To quickly design, implement, and disseminate a pharmacy-based point-of-care testing program during a public health crisis. PRACTICE DESCRIPTION: Community pharmacies in Idaho were engaged in the state's public health efforts to boost severe acute respiratory syndrome coronavirus 2 testing statewide. Geographic location was a major recruitment factor. Two recruitment periods were held to extend the Program's reach into more remote underserved communities. PRACTICE INNOVATION: Program and pharmacy staff developed workflows and materials in an iterative process. Pharmacies received testing supplies. Program staff created e-Care plans for documentation and reimbursement and designed a Web portal for state reporting of positive rapid antigen test results. EVALUATION METHODS: Testing data (pharmacy location, patient insurance status, test type and results, number of submitted Medicaid claims) were captured in an online form. RESULTS: From September to December 2020, 13 pharmacies opted into a drive-thru, rapid antigen point-of-care testing and nasal swab for offsite testing program. A total of 2425 tests were performed. Approximately 29.4% of point-of-care tests were positive, and 70.6% required backup polymerase chain reaction confirmatory analysis. Patient insurance breakdown was 72.1% private, 8% Medicare, 11.4% Medicaid, and 8.5% uninsured. On average, pharmacies tested patients an average of 2.3 hours/day and 2.6 days/week. As a group, they provided 77.5 hours of testing per week statewide. Program pharmacies accounted for an average of 5.1% of testing across the entire state at the end of December 2020. CONCLUSION: Independent community-based pharmacies should be considered as partners in public health initiatives.


Subject(s)
COVID-19 , Community Pharmacy Services , Pharmacies , Aged , COVID-19 Testing , Humans , Medicare , SARS-CoV-2 , United States , Workflow
3.
J Opioid Manag ; 13(5): 335-340, 2017.
Article in English | MEDLINE | ID: mdl-29199399

ABSTRACT

OBJECTIVE: To determine if the use of toothpicks infused with flavoring and flavoring plus the food additive spilanthol (Xerosticks™) improve saliva flow in people with opioid-induced dry mouth. DESIGN: Time series, nonrandomized, double-blind within-subject design. SETTING: Private practice/academic multidisciplinary pain and palliative care clinic. PARTICIPANTS: Ten subjects with opioid-induced dry mouth were recruited, and all finished the study. METHODS: Salivary flow and pH were measured consecutively at baseline, following use of a mango-flavored toothpick, and again after use of a mango-flavored toothpick infused with spilanthol. Salivary flow rates and saliva pH were compared between flavored and baseline, between flavored + spilanthol and baseline, and between the flavored and flavored + spilanthol. Mouthfeel of each toothpick was assessed using the Bluestone Mouthfeel Questionnaire. OUTCOMES: The primary measure was salivary flow, and the secondary measures were salivary pH and mouthfeel. RESULTS: Saliva flow increased 440 percent over baseline with use of a flavored toothpick and 628 percent over baseline with similarly flavored toothpicks infused with spilanthol, and these differences are significant (p = 0.00002). Saliva pH increased with both toothpicks (p = 0.04). The addition of spilanthol produced a greater increase in salivary flow (p = 0.05) compared to control toothpicks with flavoring alone. Furthermore, addition of spilanthol improved the "mouthfeel" of the toothpick (p = 0.00001). CONCLUSIONS: Toothpicks infused with either flavoring or flavoring plus spilanthol are likely to be an effective remedy for opioid-induced dry mouth. Addition of spilanthol may improve effectiveness over flavoring alone and may be better ac-cepted because spilanthol appears to improve mouthfeel.


Subject(s)
Analgesics, Opioid/adverse effects , Flavoring Agents/administration & dosage , Polyunsaturated Alkamides/administration & dosage , Salivary Glands/drug effects , Salivation/drug effects , Xerostomia/drug therapy , Administration, Oral , Double-Blind Method , Female , Flavoring Agents/adverse effects , Humans , Hydrogen-Ion Concentration , Male , Patient Satisfaction , Pilot Projects , Polyunsaturated Alkamides/adverse effects , Recovery of Function , Saliva/metabolism , Salivary Glands/metabolism , Salivary Glands/physiopathology , Surveys and Questionnaires , Time Factors , Treatment Outcome , Xerostomia/chemically induced , Xerostomia/diagnosis , Xerostomia/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...